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ARTICLE INFO ABSTRACT
Background: Our study aimed to elucidate the possible relationship between apoptosis,
inflammation, and fibrosis in hepatitis C virus (HCV) patients.
Methods: Patients aged 18 to 60 years with HCV were included and underwent clinical and
pathological examinations. Patients with chronic renal failure, malignancies, alcohol abuse, or
pregnancy and/or those who were taking immunosuppressant agents were excluded. Body mass
index, glucose, insulin, HOMA-IR, lipid profile, and the extent of fibrosis (METAVIR) were
determined, as were the serum levels of CK-18 (M30-Apoptosense, ELISA - Lausen, Switzerland),
Fas, Fas-L, I-CAM, V-CAM, MIF, and PAI (HSEP-63k, Milliplex, Millipore, Copenhagen,
Denmark).
Results: Of the 55 patients, 23 were treatment-naïve, 15 demonstrated a sustained virologic
response (SVR) and 17 were non-responders (NR). The levels of CK-18 did not differ between the
groups. Inflammation, as assessed by sVCAM, was directly associated with advanced fibrosis (p =
0.009). sFas-L and sVCAM were increased in the SVR group compared with the treatment-naïve
group (p = 0.006 and 0.019, respectively). sVCAM was associated with both sFas-L (rs = 0.778, p <
0.001) and MIF (rs = 0.621, p < 0.001). MIF and sFas-L were also correlated (rs = 0.526, p = 0.001).
Conclusions: Advanced fibrosis was positively correlated with inflammation according to the levels
of sVCAM. Furthermore, apoptosis, as assessed by the levels of sFas-L, and inflammation, as
determined by sVCAM, were increased in the patients who achieved viral clearance compared with
the treatment-naïve patients. The patients with advanced fibrosis were also more likely to present
with higher levels of MIF.
INTRODUCTION
It is estimated that approximately 170 million people are
chronically infected with hepatitis C virus (HCV) [1], which
represents approximately 2-3% of the world population. In
Brazil, few studies have assessed the prevalence of HCV. A
recent population-based study conducted by the Brazilian
Ministry of Health that included 19,634 individuals revealed
that the prevalence of anti-HCV antibodies was 1.38% [2].
Several factors may influence the natural history of hepatitis C
with respect to its progression to liver cirrhosis. Approximately
5% to 20% of patients with moderate to severe liver
inflammation will develop cirrhosis after 20-30 years of disease
[3]. Some of the factors that are related to the accelerated
progression of fibrosis are male gender, age at infection,
alcoholism, co-infection with hepatitis B virus (HBV) or
human immunodeficiency virus (HIV), and the presence of
steatosis or steatohepatitis [4]. The age at which patients are
infected with HCV has proven to be the best predictor of
disease progression. In older individuals, increased rates of
fibrosis progression may be related to oxidative stress,
decreased hepatic blood flow, reduced immune activity, or
mitochondrial toxicity [5].
The most significant features associated with fibrosis and liver
regeneration are hepatocellular apoptosis and cytokine-induced
inflammation. It has recently been suggested that the
susceptibility to liver fibrosis induced by HCV is related to
genes that regulate apoptosis. The most representative study
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involved a French and Swiss cohort of more than 1000 patients,
which investigated the genetic susceptibility of patients with
chronic hepatitis C (HCC) to liver fibrosis. This study
concluded that the progression of liver fibrosis is closely linked
to genomic variants that are associated with the apoptosis of
hepatocytes [6]. With regard to the processes of inflammation
and liver fibrosis, hepatic stellate cells (HSCs) are responsible
for the recruitment of inflammatory cells into the liver
parenchyma, along with intercellular and vascular adhesion
molecules. HSCs are also responsible for the recruitment of
inflammatory cytokines and are essential in the initialisation
step of fibrosis. The adhesion molecules, which belong to the
immunoglobulin family, precede the recruitment of
inflammatory cells to extravascular sites of inflammation and
are essential for the initiation of this process [7]. Our study
aimed to elucidate the possible interaction between apoptosis,
inflammation, and fibrosis in patients with chronic HCV. We
measured the serum levels of markers of apoptosis and
inflammation in selected patients with chronic HCV infection
who were either treatment-experienced or treatment-naïve, and
we correlated these markers with hepatic fibrosis.
METHODS
This was a cross-sectional study of patients from the
Department of Gastroenterology/Viral Hepatitis of the Hospital
de Clinicas de Porto Alegre (HCPA, Porto Alegre, Brazil).
Patients with HCV, as determined by the presence of anti-HCV
antibodies (ELISA) and confirmed by the presence of HCV
RNA (> 50 IU/ml) by polymerase chain reaction (PCR), were
evaluated for inclusion in this study. Patients with HCV
monoinfections who were aged from 18 to 60 years underwent
both clinical and pathological examinations. Patients with
chronic renal failure, malignancies, alcohol abuse, or
pregnancy and/or those who were taking immunosuppressant
agents were excluded. Body mass index, the levels of glucose
and insulin, HOMA-IR, lipid profile, and the extent of fibrosis
(METAVIR) were determined, as were the serum levels of CK-
18 (M30-Apoptosense, ELISA - Lausen, Switzerland), Fas,
Fas-L, I-CAM, V-CAM, MIF, and PAI (HSEP-63k, Milliplex,
Millipore, Copenhagen, Denmark). The patients were divided
into three groups: treatment-naïve, those with a sustained
virologic response (SVR), and non-responders (NR). The
measurements were performed in duplicate according to the
manufacturers’ guidelines. The study was approved by the
Ethical Committee of the HCPA and conformed to the ethical
guidelines of the Declaration of Helsinki. Informed consent
was obtained from all included patients.
Histological Analysis
Liver biopsies were evaluated irrespective of the presence of
other markers. Histological features were analysed with the
METAVIR group scoring system. Fibrosis was staged on a
scale of F0 to F4 as follows: F0 = no fibrosis, F1 = portal
fibrosis without septa, F2 = few septa, F3 = numerous septa
without cirrhosis, and F4 = cirrhosis. Scores of F0, F1, or F2
indicated initial fibrosis, while scores of F3 or F4 indicated
advanced fibrosis.
Statistical Analysis
The data were entered into Excel and then exported to SPSS
version 18.0 for statistical analysis. The frequencies and
percentages of the categorical variables were obtained.
Quantitative variables with normal distributions were described
by the mean and standard deviation, and variables with
asymmetric distributions were described by the median and
interquartile range (25th and 75th percentiles). Categorical
variables were compared by Fisher's exact test or the chi-square
test. Quantitative variables with normal distributions were
compared by Student's t test for independent samples or by
analysis of variance (ANOVA) followed by a post hoc Tukey
test. Quantitative variables with skewed distributions were
compared by the Mann-Whitney U test or the Kruskal-Wallis
test. A significance level of 5% was considered for established
comparisons.
RESULTS
Patient Characteristics
Fifty-five patients with a mean age of 47.3 years were included.
These patients were predominantly female (65.5%), and most
were infected with HCV genotype 1 (75.6%) and presented
with grade 2 fibrosis according to the METAVIR index
(41.8%). The percentage of steatosis according to the liver
biopsies was less than 5% in all samples. Table 1 shows the
demographic and clinical characteristics of the patients who
were included in this study. Most of the patients were female
and were infected with HCV genotype 1. The age of the
patients was similar in the 3 groups. With regard to the
METAVIR index, the majority of patients presented with early
fibrosis (F0 to F2) (p = 0.055).
Table 2 shows the results of the laboratory tests that were
conducted and evaluated in the study population. Higher levels
of triglycerides were observed in the non-responders compared
with the SVR patients (p = 0.009).
Table 1 Demographic and clinical characteristics of the
study population
Characteristics Naïve
n = 23
SVR
n = 15
NR
n = 17 p
Age  (average/SD) 45 (8) 48 (9) 51 (8) 0.090
Female (%) 65.2 66.7 64.7 0.993
Genotype 1 (%) 71.4 66.7 100 0.154
METAVIR F0 - F2 (%) 95.5 66.7 70.6 0.055
Naïve= untreated patients, SVR = sustained virologic response, NR = non-responders, SD =
standard deviation.
Variables with a symmetric distribution were described by the mean (standard deviation) and
were compared by analysis of variance (ANOVA). Categorical variables were described by
percentages and were compared by the chi-square test.
Table 2 Laboratory tests conducted in the study
population
Variables Naïve
n = 23
SVR
n = 15
NR
n = 17 p
AST 42 (24 – 79) 43 (20 – 200) 38 (12 – 107) 0.843
ALT 47 (22 – 223) 62 (22 – 407) 44 (18 - 77) 0.471
Total cholesterol 161 (32) 166 (29) 171 (24) 0.577
HDL cholesterol 48 (12) 47 (16) 48 (16) 0.994
Triglycerides 114 (50 – 576)a, b 88 (56 – 201)a 122 (71 – 294)b 0.009
Glycaemia 95 (10) 97 (6) 103 (17) 0.105
BMI 29 (4)a 25 (3)b 25 (3)a, b 0.020
Insulin 15 (5 – 90) 12 (6 – 35) 13 (6 – 22) 0.535
HOMA-IR 3  (1 – 10) 3 (2 – 8) 3 (1 – 6) 0.567
Naïve = untreated patients, SVR = sustained virologic response, NR = non-responders, AST =
aspartate aminotransferase, ALT = alanine aminotransferase, HDL = high-density lipoprotein,
BMI = body mass index, HOMA-IR = homeostatic model assessment insulin resistance.
Variables with asymmetric distributions were described by the median (minimum-maximum) and
were compared by the Kruskal-Wallis test. Variables with symmetric distributions were described
by the mean (standard deviation) and were compared by analysis of variance (ANOVA).
a, b: The different letters represent significantly different distributions.
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Although obese individuals were excluded, BMI values were
higher in the naïve group compared with the SVR group (p =
0.020). No differences were observed in the levels of
aminotransferases, cholesterol, glucose, and insulin or in the
HOMA-IR.
Table 3 shows the levels of inflammatory and apoptotic
markers in the different groups. The levels of Fas and sVCAM-
I were higher in patients with SVR compared with treatment-
naïve patients (p = 0.006 and p = 0.019, respectively). No
significant differences were found in the levels of CK-18, MIF,
sICAM-1, sFas, or tPAI-1.
The level of sVCAM-I demonstrated a direct and statistically
significant correlation with the level of sFas-L (rs = 0.778, p <
0.001) and with the level of MIF (rs = 0.621, p < 0.001). The
levels of sFas-L and MIF were also directly correlated (rs =
0.526, p < 0.001).
The distribution of hepatic fibrosis was evaluated and is shown
in Figure 1.
The frequency of METAVIR scores of F0 and F1 was higher in
the naïve group (p = 0.001).
Table 4 shows the levels of inflammatory and apoptotic
markers in the different groups. The level of the inflammatory
marker sVCAM-I was higher in patients with advanced fibrosis
compared with patients with early fibrosis (p = 0.009). No
significant differences were found in any of the other variables
(i.e., CK-18, MIF, sICAM-1, sFas-L, sFas, and tPAI-1).
Additionally, we compared 41 patients with fibrosis
(METAVIR score of F1 to F4) and 13 patients without fibrosis
(METAVIR F0), and the following medians were obtained
(Mann-Whitney test): CK-18 = 350.81 vs. 182.00, p = 0.716;
MIF = 1148.47 vs. 536.47, p = 0.731; s-ICAM-1 = 126179.80
vs. 117042.66, p = 0.664; sFas-L = 32.99 vs. 21.49, p = 0.310;
sFas = 3863.5 vs. 2925.0; p = 0.911, sVCAM-1 = 318904.04
vs. 300785.66, p = 0.407; and tPAI-1 = 59567.60 vs. 54266.96,
p = 0.237.
DISCUSSION
The progression of HCV-induced liver disease and the response
to therapy are strongly influenced by viral and host genetic
factors, including the genotype of the virus and genetic
polymorphisms, such as those in the IL28B gene [8]. Several
authors have suggested an association between apoptosis and
the progression of hepatic fibrosis. Initially, patients with
hepatic steatosis and steatohepatitis were studied, and apoptotic
markers were used to differentiate these two groups [9–11].
These studies were able to distinguish patients with non-
alcoholic steatohepatitis (NASH) from those with more
advanced fibrosis, but they included heterogeneous
populations, such as patients with cirrhosis, diabetes, or cancer
or those who had received some type of immunosuppressive
therapy. These apoptotic markers were assessed in patients
with HCV and demonstrated, in addition to their usefulness in
the assessment of liver fibrosis progression, utility in the
monitoring of the treatment of patients with interferon and
Table 3 Inflammatory and apoptotic markers in the study
population
Naïve
n = 23
SVR
n = 15
NR
n = 17 p
CK-18 (UI/L) 214(66 – 2435)
141
(74 – 1146)
204
(74 – 655) 0.497
MIF (pg/mL) 440(85 – 8129)
1070
(263 – 5636)
646
(184 – 4098) 0.058
sICAM-I
(pg/mL)
78449
(21113–
615688)
87247
(33478 – 688432)
92949
(23924 - 380726) 0.326
sFas-L
(pg/mL)
17
(13 – 82)a
32
(16 – 121)b
27
(13 - 93)a,b 0.006
sFas (pg/mL) 2475(671 – 18928)
3737
(1614 - 9814)
3499
(1160 - 6541) 0.197
sVCAM-I
(pg/mL)
183606
(61422 –
525642)a
356023
(94693 – 777287)
b
331118
(105247 -
757969)a,b
0.019
tPAI-1
(pg/mL)
54267
(18589 -
200570)
53884
(18878 - 149866)
42570
(14211 - 135330) 0.459
Naïve = untreated patients, SVR = sustained virologic response, NR =
non-responders, CK-18 = cytokeratin 18, MIF = migration inhibitory
factor of macrophages, sICAM-I = soluble intercellular adhesion
molecule type 1, sFas = soluble protein associated with apoptosis, sFas-
L = binding protein soluble, sVCAM-I = soluble vascular adhesion
molecule type 1, tPAI-1 = plasminogen activator inhibitor
Variables with asymmetric distributions were described by the median
(minimum-maximum) and were compared by the Kruskal-Wallis test.
a, b Different letters represent different statistical distributions.
Figure 1 Distribution of different degrees of fibrosis according to the
METAVIR classification in the studied groups.
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Table 4 The levels of inflammatory and apoptotic markers
with respect to the degree of fibrosis observed after liver
biopsy
Initial fibrosis (n = 44) Advanced fibrosis(n = 11) p
CK-18 (UI/mL) 182.14(139.28 – 360.57)
214.55
(88.23 – 655.17) 0.430
MIF (pg/mL) 618.47(216.51 – 1393.70)
1272.37
(645.73 – 2458.90) 0.053
sICAM-1
(pg/mL)
79015.87
(40960.01 – 173696.93)
117405.30
(83212.45 – 156393.60) 0.178
sFas-L (pg/mL) 24.83(14.72 – 36.06)
27.11
(20.41 – 70.65) 0.180
sFas (pg/mL) 2966.85(1643.65 – 5081.11)
3737.01
(3378.28 – 5116.80) 0.132
sVCAM-1
(pg/mL)
209039.08
(133962.45 –
366003.85)
400044.70
(246807.05 – 656279.56) 0.009
tPAI-1 (pg/mL) 45961.60(34618.25 – 102330.36)
51563.88
(40697.07 – 66589.07) 0.866
CK-18 = cytokeratin 18, MIF = inhibitor of macrophage migration factor,
sICAM-I = soluble intercellular adhesion molecule type 1, sFASL =
soluble binding protein, sFAS = soluble protein associated with apoptosis,
sVCAM-I = soluble vascular cell adhesion molecule type 1, tPAI-1 =
plasminogen activator inhibitor
Variables were described by the median (interquartile range: P25 to P75)
and were compared with the Mann-Whitney test.
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ribavirin [12–14]. Some studies included low numbers of
patients and did not exclude patients with NASH and with
possible apoptotic activity from other causes. In 2012, a cohort
study highlighted the genomic variants that are associated with
hepatocyte apoptosis, and this study revealed a correlation
between these genomic variants and the progression of liver
fibrosis [6]. Our study included 55 patients with HCV. We
found higher serum levels of apoptotic markers (CK-18, sFas,
and sFas-L) in the population with more advanced fibrosis.
This finding is consistent with results in the literature but was
not significant. Repeating the study with an increased sample
size may reveal statistically significant differences in
populations with different stages of fibrosis.
HCV infection leads to inflammatory processes of different
grades that involve the activation of adhesion molecules and
cytokines that facilitate the recruitment of leukocytes to areas
of inflammation [15]. Liver fibrosis follows hepatic
inflammation as a result of hepatocyte injury [16]. The
interactions between membrane receptors on HSCs and
extracellular matrix proteins are regulated by adhesion
molecules [17,18]. sVCAM-I and sICAM-I play key roles in
leukocyte adhesion via the activation of HSCs and the
propagation of liver fibrosis. Some authors have reported that
the circulating levels of these molecules are related to hepatic
inflammatory activity and fibrosis score [19,20]. Other authors
have indicated that patients with HCV infection who were
treated with interferon had decreased circulating levels of
ICAM-I if they attained an SVR [21,22]. In contrast, a 2009
study assessed the levels of this marker in patients with HCV
before and after antiviral treatment and revealed that sVCAM-I
levels were higher in patients with more advanced stages of
fibrosis, but the levels did not predict treatment response [15].
Subsequently, another study [23] including 134 patients with
chronic liver disease concluded that the VCAM level is related
to a Child-PughC. Our study shows that patients with advanced
fibrosis have higher levels of sVCAM-1 compared with
patients with early fibrosis; in addition, the serum levels of
sVCAM-1 were higher in patients with SVR compared with
treatment-naïve patients.
The role of MIF in leukocyte recruitment and in the
interference of the activation of HSCs in chronic inflammatory
diseases of the liver has not been well studied. The most
representative study was published in 2011. The authors
reported that in a murine model, MIF has an antifibrotic role
and inhibits the activation of HSCs via the CD74 receptor [24].
Thus, the use of MIF as a target for therapy for chronic liver
disease was suggested. Our study shows that patients with
advanced fibrosis (p = 0.053) and those with an SVR (p =
0.058) are more likely to have higher levels of MIF. We also
found a strong correlation between the levels of MIF and
sVCAM-I (rs = 0.621, p < 0.001) and between the levels of
MIF and sFas-L (rs = 0.526, p < 0.001). In our study, patients
with viral clearance presented with higher levels of sVCM-1
and sFas-L, which may justify the higher MIF levels found.
Few studies on tPAI-1 and hepatic fibrosis are present in the
literature. It has been shown that hyperfibrinolysis occurs in
chronic liver disease along with reduced levels of plasminogen,
increased levels of PAI, and an imbalance of the procoagulant
system [25]. Two main hypotheses have been presented with
regard to coagulation and the progression of liver fibrosis. One
hypothesis involves the formation of microthrombi in the portal
system, which leads to tissue ischaemia, death, and fibrosis of
the liver parenchyma [26]. The other hypothesis suggests that
the activation of coagulation in the vascular system may play a
role in the progression of liver disease via thrombin signalling
of HSCs [27]. A recent study suggested an association between
elevated levels of tPAI-1 and SVR and showed an inverse
correlation between tPAI-1 and liver fibrosis [28]. Our study
found no significant difference in the population studied.
This study has some strength that should be emphasised. We
evaluated the relationship of markers of fibrosis, apoptosis, and
inflammation in a homogeneous sample. We excluded obese
patients as well as those with diabetes and steatohepatitis, as
these are important confounding factors in HCV-induced liver
damage. Additionally, we included treated and untreated
patients and aimed to understand the behaviour of these
markers in the process of viral clearance. However, our study
was limited by the small sample size and the inclusion of only a
few patients with advanced fibrosis.
CONCLUSION
We conclude that patients with advanced fibrosis have higher
levels of inflammation as measured by the level of sVCAM-1.
Additionally, patients who achieved an SVR had higher levels
of serum markers of apoptosis and inflammation, as determined
by the levels of sFas-L and sVCAM-1, compared with
treatment-naïve patients.
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